Tag: Samsung Bioepis

Biogen expands its ownership in Samsung Bioepis

Biogen announced it has exercised its option to purchase additional shares of Samsung Bioepis Co., Ltd., a joint venture established in 2012 by Samsung BioLogics and Biogen.

AbbVie reached a resolution in intellectual property-related dispute

AbbVie announced it reached a global resolution for all intellectual property-related litigation with the two companies regarding its biosimilar Imraldi (adalimumab).

Samsung Bioepis biosimilar cancer drug begun to sell in Europe

Korean biopharmaceutical firm Samsung Bioepis informed that its biosimilar cancer drug Ontruzant has begun selling in Britain following approval from a European regulator (EMA).

Samsung Bioepis received EU approval for its Herceptin biosimilar

Samsung Bioepis announced the European Commission’s marketing authorization of ONTRUZANT, a biosimilar referencing Herceptin (trastuzumab)

Samsung Bioepis and Takeda will jointly develop new drugs

Samsung Bioepis Co., Ltd. announced that it has entered into a strategic collaboration agreement with Takeda Pharmaceutical Company